Trial Profile
A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; Carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms BOLERO-1
- Sponsors Novartis; Novartis Pharmaceuticals
- 02 Jul 2019 This trial has been completed in France (End Date:23 Oct 2017), according to European Clinical Trials Database record.
- 15 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 07 Sep 2017 Planned End Date changed from 30 May 2018 to 13 Oct 2017.